
RVNC
Healthcare · Biotechnology · $381.0M market cap
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2024
EPS trend, 90 days to now · -116.2% over 90 days · 30-day revisions 0 up, 1 down
Beat estimates in 4 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 4, 2024 | After the close | -0.38 | -0.37 | +2.6% |
| Aug 8, 2024 | After the close | -0.53 | -0.36 | +32.1% |
| May 9, 2024 | After the close | -0.75 | -0.58 | +22.7% |
| Feb 28, 2024 | After the close | -0.72 | -0.62 | +13.9% |
| Nov 8, 2023 | After the close | -0.85 | -1.63 | -91.8% |
| Aug 8, 2023 | After the close | -0.78 | -0.80 | -2.6% |
| May 9, 2023 | After the close | -0.70 | -0.74 | -5.7% |
| Feb 28, 2023 | After the close | -0.95 | -0.95 | 0.0% |
| Nov 8, 2022 | After the close | -0.89 | -1.17 | -31.5% |
| Aug 9, 2022 | After the close | -0.86 | -0.88 | -2.3% |
| May 10, 2022 | After the close | -0.83 | -0.94 | -13.3% |
| Feb 28, 2022 | After the close | -1.00 | -0.93 | +7.0% |
| Nov 9, 2021 | After the close | -1.15 | -1.10 |
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to…
| +4.3% |
| Aug 5, 2021 | After the close | -1.05 | -1.07 | -1.9% |
| May 10, 2021 | After the close | -1.09 | -1.08 | +0.9% |
| Feb 22, 2021 | After the close | -1.24 | -1.24 | 0.0% |
| Nov 9, 2020 | After the close | -1.03 | -1.34 | -30.1% |
| Aug 6, 2020 | After the close | -1.01 | -1.10 | -8.9% |
| May 7, 2020 | After the close | -0.90 | -1.15 | -27.8% |
| Feb 24, 2020 | After the close | -0.97 | -0.99 | -2.1% |
| Nov 4, 2019 | After the close | -0.98 | -0.96 | +2.0% |
| Aug 5, 2019 | After the close | -0.91 | -0.86 | +5.5% |
| May 8, 2019 | After the close | -0.87 | -0.85 | +2.3% |
| Feb 26, 2019 | After the close | -0.94 | -1.12 | -19.1% |
| Nov 1, 2018 | After the close | -0.97 | -0.91 | +6.2% |
| Aug 2, 2018 | After the close | -0.94 | -0.94 | 0.0% |
| May 8, 2018 | After the close | -0.71 | -0.97 | -36.6% |
| Feb 28, 2018 | After the close | -0.97 | -1.14 | -17.5% |